Invivyd, Inc. Files 8-K
Ticker: IVVD · Form: 8-K · Filed: Apr 4, 2024 · CIK: 1832038
| Field | Detail |
|---|---|
| Company | Invivyd, INC. (IVVD) |
| Form Type | 8-K |
| Filed Date | Apr 4, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $150 Million, $200 Million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, biotech
TL;DR
Invivyd filed an 8-K on 4/4/24. Standard corporate update.
AI Summary
Invivyd, Inc. (formerly Adagio Therapeutics, Inc.) filed an 8-K on April 4, 2024, reporting other events and financial statements. The company, incorporated in Delaware, is in the biological products sector and is headquartered in Waltham, MA.
Why It Matters
This filing indicates routine corporate reporting, including financial statements and other events, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for corporate reporting and does not contain any specific material events that would inherently increase risk.
Key Numbers
- 001-40703 — SEC File Number (Identifies the company's filing with the SEC.)
- 85-1403134 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Invivyd, Inc. (company) — Registrant
- Adagio Therapeutics, Inc. (company) — Former Name
- April 4, 2024 (date) — Date of Report
- Waltham, MA (location) — Principal Executive Offices
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The provided text does not detail the specific 'Other Events' beyond listing it as an item information category.
What is the primary business of Invivyd, Inc.?
Invivyd, Inc. is in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) sector, SIC code 2836.
When did Invivyd, Inc. change its name from Adagio Therapeutics, Inc.?
The date of the name change from Adagio Therapeutics, Inc. to Invivyd, Inc. was November 12, 2020.
Where are Invivyd, Inc.'s principal executive offices located?
Invivyd, Inc.'s principal executive offices are located at 1601 Trapelo Road, Suite 178, Waltham, MA 02451.
What is the fiscal year end for Invivyd, Inc.?
Invivyd, Inc.'s fiscal year ends on December 31st.
Filing Stats: 480 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-04-04 17:25:56
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share IVVD The Nasdaq Stock Mar
- $150 Million — roduct Revenue Guidance in the Range of $150 Million to $200 Million". A copy of the press r
- $200 Million — uidance in the Range of $150 Million to $200 Million". A copy of the press release is filed
Filing Documents
- d818209d8k.htm (8-K) — 24KB
- d818209dex991.htm (EX-99.1) — 21KB
- d818209dex992.htm (EX-99.2) — 13KB
- g818209ex99_2p1g1.jpg (GRAPHIC) — 317KB
- g818209ex99_2p2g1.jpg (GRAPHIC) — 817KB
- g818209ex99_2p3g1.jpg (GRAPHIC) — 136KB
- g818209ex99_2p4g1.jpg (GRAPHIC) — 378KB
- g818209ex99_2p5g1.jpg (GRAPHIC) — 298KB
- g818209ex99_2p6g1.jpg (GRAPHIC) — 240KB
- g818209ex99_2p7g1.jpg (GRAPHIC) — 362KB
- g818209ex99_2p8g1.jpg (GRAPHIC) — 174KB
- g818209ex99_2p9g1.jpg (GRAPHIC) — 176KB
- 0001193125-24-087408.txt ( ) — 4185KB
- ivvd-20240404.xsd (EX-101.SCH) — 3KB
- ivvd-20240404_lab.xml (EX-101.LAB) — 18KB
- ivvd-20240404_pre.xml (EX-101.PRE) — 11KB
- d818209d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INVIVYD, INC. Date: April 4, 2024 By: /s/ Jill Andersen Jill Andersen Chief Legal Officer and Corporate Secretary